title: A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.
abstract: The choice of appropriate artemisin-based combination therapy depends on several factors (cost, efficacy, safety, reinfection rate, and simplicity of administration). In this study, we tested the hypothesis that artesunate-mefloquine (Artequin) is as efficacious as artemether-lumefantrine (Coartem) in treatment of uncomplicated Plasmodium falciparum malaria. The study was carried out from August 2004 through February 2005 in Kambila, Mali. Subjects with weights >/= 10 kg and uncomplicated malaria were enrolled. Artesunate-mefloquine was given once a day for three days and artemether/lumefantrine twice a day for three days. A total of 470 (235 in each arm) patients were enrolled. The unadjusted 28-day cure rate was higher in artesunate-mefloquine arm than in the artemether-lumefantrine arm (79.7% versus 67.8%; P < 0.004). After correction for reinfection, the 28-day cure rates were similar in the two groups (96.04% versus 96.93%). Artesunate-mefloquine is well-tolerated and is as effective as artemether-lumefantrine for the treatment of P. falciparum malaria. Artesunate-mefloquine also prevented more new infections.
authors.affiliation: Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Odonto-Stomatology, University of Bamako, Bamako, Mali. isagara@mrtcbko.org
authors.forename: Issaka
authors.initials: I
authors.lastname: Sagara
authors.forename: Abdoulbaki
authors.initials: A
authors.lastname: Diallo
authors.forename: Mamady
authors.initials: M
authors.lastname: Kone
authors.forename: Modibo
authors.initials: M
authors.lastname: Coulibaly
authors.forename: Sory Ibrahima
authors.initials: SI
authors.lastname: Diawara
authors.forename: Ousmane
authors.initials: O
authors.lastname: Guindo
authors.forename: Hamma
authors.initials: H
authors.lastname: Maiga
authors.forename: Mohamed Balla
authors.initials: MB
authors.lastname: Niambele
authors.forename: Mady
authors.initials: M
authors.lastname: Sissoko
authors.forename: Alassane
authors.initials: A
authors.lastname: Dicko
authors.forename: Abdoulaye
authors.initials: A
authors.lastname: Djimde
authors.forename: Ogobara K
authors.initials: OK
authors.lastname: Doumbo
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D000077549:Artemether; D037621:Artemisinins / Q000008:administration & dosage / Q000627:therapeutic use*; D000077332:Artesunate; D001483:Base Sequence; D017931:DNA Primers; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D005449:Fluorenes / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D000078102:Lumefantrine; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008302:Mali; D015767:Mefloquine / Q000008:administration & dosage / Q000627:therapeutic use*; D010963:Plasmodium falciparum / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction; D016896:Treatment Outcome
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D017931:DNA Primers; D004983:Ethanolamines; D005449:Fluorenes; D000077332:Artesunate; D000077549:Artemether; D000078102:Lumefantrine; D015767:Mefloquine